Summary
The EnligHTN renal denervation system reduced office blood pressure (BP) with no serious periprocedural adverse events over 24 months of follow-up. This article presents long-term data from the first-in-human Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients trial [EnligHTN I; NCT01438229].
- Cardiology Clinical Trials
- Hypertension & Kidney Disease
- Interventional Techniques & Devices
- Hypertensive Disease
- Renal Disease
- Cardiology & Cardiovascular Medicine
- Cardiology Clinical Trials
- Hypertension & Kidney Disease
- Interventional Techniques & Devices
- Hypertensive Disease
- Renal Disease
- © 2014 MD Conference Express®
Tools
BP Reduction by Renal Denervation Maintained over 24 Months in the EnligHTN I Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.